Pimm M V, Armitage N C, Perkins A C, Smith W, Baldwin R W
Cancer Immunol Immunother. 1985;19(1):8-17. doi: 10.1007/BF00199305.
A mouse monoclonal anti-CEA antibody (11.285.14) has been examined for tumour localization potential by assessing its distribution in immunodeprived mice with xenografts of human colon carcinoma cell lines HCT-8, HRT-18, HT-29, and LS174T and a xenograft (HRVB) established from a primary rectal carcinoma. With four carcinomas (HCT-8, HT-29, LS174T, and HRVB) preferential tumour localization of 125I anti-CEA was seen. Compared with 131I normal IgG1 localization indices of up to 4.4:1 were achieved. Up to 10% of the injected dose of 125I anti-CEA was present/g of tumour tissue and with the largest xenografts examined (3-4 g) up to 40% of the total body reactivity was localized in tumour tissue. The tumour localization of 131I labelled antibody was visualized by external gamma camera imaging. Overall antibody localization correlated with the CEA content of the xenografts and the fourth colon carcinoma xenograft (HRT-18) and an osteogenic sarcoma xenograft (791T), both with very low CEA levels, showed no localization of the monoclonal antibody.
通过评估一种小鼠单克隆抗癌胚抗原（CEA）抗体（11.285.14）在免疫缺陷小鼠体内的分布情况，研究了其肿瘤定位潜力。免疫缺陷小鼠体内移植了人结肠癌细胞系HCT-8、HRT-18、HT-29和LS174T以及一株源自原发性直肠癌的异种移植瘤（HRVB）。在四种癌组织（HCT-8、HT-29、LS174T和HRVB）中观察到125I标记的抗CEA抗体有优先的肿瘤定位现象。与131I标记的正常IgG1相比，定位指数高达4.4:1。每克肿瘤组织中存在高达10%的注入剂量的125I抗CEA，在检查的最大异种移植瘤（3 - 4克）中，高达40%的全身反应性定位于肿瘤组织。131I标记抗体的肿瘤定位通过外部γ相机成像进行可视化。总体抗体定位与异种移植瘤的CEA含量相关，第四种结肠癌异种移植瘤（HRT-18）和成骨肉瘤异种移植瘤（791T）的CEA水平都非常低，未显示单克隆抗体的定位。
